News
ASND
255.96
-5.32%
-14.37
Ascendis Pharma Is Maintained at Overweight by Barclays
Dow Jones · 3d ago
Barclays Maintains Overweight on Ascendis Pharma, Raises Price Target to $341
Benzinga · 3d ago
Ascendis Pharma price target raised to $341 from $329 at Barclays
TipRanks · 4d ago
Weekly Report: what happened at ASND last week (1109-1113)?
Weekly Report · 4d ago
Citi Sticks to Their Buy Rating for Ascendis Pharma (ASND)
TipRanks · 4d ago
Analysts Are Bullish on Top Healthcare Stocks: Twist Bioscience (TWST), Ascendis Pharma (ASND)
TipRanks · 4d ago
Ascendis Pharma (ASND) Stock Looks Reasonable Following Its 22% Run
Simply Wall St · 5d ago
RBC Capital Remains a Buy on Ascendis Pharma (ASND)
TipRanks · 6d ago
Ascendis Pharma Is Maintained at Buy by UBS
Dow Jones · 6d ago
UBS Maintains Buy on Ascendis Pharma, Raises Price Target to $315
Benzinga · 6d ago
Ascendis Pharma Is Maintained at Overweight by Wells Fargo
Dow Jones · 6d ago
Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $330
Benzinga · 6d ago
Ascendis Pharma Price Target Maintained With a $290.00/Share by RBC Capital
Dow Jones · 6d ago
RBC Capital Reiterates Outperform on Ascendis Pharma, Maintains $290 Price Target
Benzinga · 6d ago
Ascendis Pharma Is Maintained at Buy by TD Cowen
Dow Jones · 6d ago
TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $352
Benzinga · 6d ago
Ascendis Pharma A/S Grants 28,030 Warrants to Employees
NASDAQ · 6d ago
Leerink Partners Keeps Their Buy Rating on Ascendis Pharma (ASND)
TipRanks · 6d ago
Bank of America Securities Sticks to Its Buy Rating for Ascendis Pharma (ASND)
TipRanks · 6d ago
Ascendis Pharma price target raised to $346 from $327 at Wedbush
TipRanks · 6d ago
More
Webull provides a variety of real-time ASND stock news. You can receive the latest news about Ascendis Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ASND
Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.